We're dipping into our deep pockets of cash to buy more of this type of healthcare stock.
We are buying 90 shares of Cardinal Health at approximately $217. Following the transaction, Jim Cramer's Charitable Trust will own…
Danaher Corp.
Why Novo Nordisk's expansion in Ireland is key to fighting Eli Lilly
Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capabilities to…
We are adding stock to our Bullpen; resilient to recessions and AI disruption
We added a new Bullpen name during Friday's monthly meeting, and it has minimal economic sensitivity and faces little to…
Danaher is making good use of mergers and acquisitions once again. But we could have had enough
Danaher's days in the portfolio may be numbered. We were once again disappointed after Danaher's latest acquisition plan failed to…
Danaher Stock Fails to Rise on Strong Earnings, Leaving Us to Wonder What's Next
Danaher shares fell Wednesday as Wall Street failed to give the supplier of tools and equipment to drugmakers and hospitals…
Why Wall Street and Jim Cramer Think Danaher Stock Is 'Ready to Play'
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does it too. Life sciences stocks are…
Jim Cramer has faith in Danaher's turnaround as life sciences come back to life
Life sciences stocks are experiencing a resurgence, and that's good news for Danaher. Connecting the dots with better times ahead…
Danaher puts bioprocessing back into growth. We are raising our rating to buy
Danaher shares fell on Tuesday even though the life sciences company regained growth in its key bioprocessing business in the…
9 stocks that can benefit from the Fed's interest rate cuts
The S&P 500 and Nasdaq extended their record rallies this week after consumer inflation data came in better than expected…
Danaher shows how holding a good company's troubled stock can pay off
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…